Bolstered by the success of KRAS G12C inhibitors in lung cancer, smaller firms are developing drugs for a range of other KRAS-mutated cancers and trying to anticipate resistance.
Erin Whitney as head of global clinical operations and
Keith White as head of global market access and has also appointed brand strategy consultant
Shauna Horvath to head of global marketing. Whitney joins the team from bluebird bio, while Merck and Genentech veteran White was most recently VP, global market access and pricing at Corbus Pharmaceuticals. Horvath joined Amylyx as a consultant in 2019.
> Culver City, California’s ImmunityBio tapped
Fabio M. Benedetti, M.D., as chief strategy officer, effective Jan. 4. Should ImmunityBio’s NantKwest merger close, Benedetti is expected to assume the role of CSO at the combined company, ImmunityBio said. Benedetti joins from combination therapy specialist Apollomics, where he was chief medical officer.